Tamoxifen, raloxifene, and the prevention of breast cancer.
Jordan
V C
VC
Department of Molecular Pharmacology, Biological Chemistry, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Medical School, Chicago, Illinois 60611, USA.
Morrow
M
M
D000818:Animals; D016588:Anticarcinogenic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D004965:Estrogen Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D006801:Humans; D010880:Piperidines / Q000494:pharmacology / Q000627:therapeutic use*; D020849:Raloxifene Hydrochloride; D011960:Receptors, Estrogen / Q000037:antagonists & inhibitors / Q000502:physiology; D012307:Risk Factors; D013629:Tamoxifen / Q000494:pharmacology / Q000627:therapeutic use*
D016588:Anticarcinogenic Agents; D004965:Estrogen Antagonists; D010880:Piperidines; D011960:Receptors, Estrogen; D013629:Tamoxifen; D020849:Raloxifene Hydrochloride